v ::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::
ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

EPIDEMIOLOGY OF NON-COMMUNICABLE RESPIRATORY DISEASES IN PAKISTAN

AUTHORS:

Dr Farhan Ahmad, Dr Zahra Ali, Dr Muaaz Akram

ABSTRACT:

Introduction: Non-communicable diseases (NCDs) are a major and increasing global health issue. According to the Global Burden of Diseases (GDB) 2015 report, there are between 39.8 and 40.5 million deaths per year from the four main categories of NCDs, namely cardiovascular diseases, diabetes, cancer, and chronic respiratory diseases (CRDs), representing 63% of all global deaths. Aims and objectives: The basic aim of the study is to analyze the epidemiology of non-communicable respiratory diseases in Pakistan. Methodology of the study: This cross sectional study was conducted at Ghurki Trust and Teaching Hospital Lahore in 2019 with the permission of ethical committee of hospital. There were 100 patients who was suffering from different kind of respiratory diseases, selected for this study. Patients of both genders were included in this research analysis. For this purpose we collect the socio-demographic data of selected participants. Results: The data was collected from 100 selected patients. There was significant association between presence of metabolic syndrome and BMI with p-value = 0.000. Significant association was found between the presence of metabolic syndrome and duration of COPD with p-value = 0.000. There was significant association between presence of metabolic syndrome and smoking with p-value = 0.000. Conclusion: It is concluded that there is, however, limited epidemiological evidence currently representing an important gap in the evidence base and need for further research. Asthma and COPD are likely to be under-estimated, under-diagnosed, under-treated as well as inadequately prevented.

FULL TEXT

<
Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.